Endocrine Abstracts

Introduction: Hypercalcemia is one of the most common endocrine disorders. Most out-patients’s cases are due to primary hyperparathyroidism and run with chronic and low-moderate hypercalcemia. We report a case of acute and severe hipercalcemia of unknown origin. Diagnostic procedure is discussed.Case report: A 53-year-old man was admitted to the Intensive Care Unit due to progressive deterioration of consciousness in the last 48 hours, associating r...

Introduction: Data from several clinical trials have shown positive effects of GLP1 analogue drugs on renal function in patients with type 2 diabetes (T2DM). However, there are very few reported results on its potential renoprotective effect in routine clinical practice. Our aim is to evaluate the effects of the addition of weekly dulaglutide (a GLP-1 analogue) to the normoglycemic treatment of patients with T2DM on renal function in a real-world cohort of patients.<p clas...

Introduction: Sodium glucose cotransporter 2 inhibitors (SGT2-i) and glucagon-like peptide-1 receptor agonists (GLP-1-ra) conform two families of drugs with beneficial effects on weight and glycemia. Our aim is to identify epidemiological and clinical characteristics of patients, candidates to receive one of these classes of drugs, that can influence on physician’s decisions.Methods/design: Retrospective observational research. Data from patients wi...

Introduction: In contrast to general population, clinical consequences related to low levels of 25-hydroxyvitamin D in HIV-infected patients with overweight are not established. The aim of our study was to investigate the influence of weight on clinical parameters and on calcium-phosphorus homeostasis in HIV-patients with vitamin D deficiency.Methods/design: Prospective study of HIV outpatients treated in our hospital. Vitamin D deficiency (D-DEF) was de...

Introduction: It is well known that the prevalence of major cardiovascular risk factors has increased in HIV-infected people since improvement of antiretroviral therapy. Currently, Spain is defined as a ‘low risk country’ for cardiovascular diseases (CVD) by 2016 European Guidelines on cardiovascular disease prevention. The objective of this study is to assess the prevalence and characteristics of CVD risk factors and risk for CVD in a cohort of HIV-infected adults l...

Introduction: Inhibitors of sodium-dependent glucose co-transporter 2 (SGLT2i) reduce circulating glucose concentrations via a renal mechanism. Its metabolic effects have not been fully described and there is a discrepancy on some clinical results found in studies on SGLT2i. Our aims were to detect if there are some predictor factors to identify what patients will have higher response to dapagliflozin, a SGLT2i, and second, to explore whether intensity of glycosuria is correla...

Introduction: In clinical trials, dapagliflozin has been shown to lower blood glucose, reduce weight and blood pressure in people with type 2 diabetes (T2D). However, there are limited published data on quantitative changes on blood pressure of this drug in routine clinical practice. Our aim was to examine the clinical efficacy of dapagliflozin in patients with T2D and hypertension in a real-life cohort.Methods/design: Prospective study including patient...

Introduction: Sodium-glucose co-transporter-2 inhibitors (SGLT2i) are a newly developed class of oral anti-diabetic drugs with a unique mechanism of action and its use is becoming more widespread. Given that dapagliflozin was the first drug of this class used in Spain, available since December 2013, 3 years after its inception, we aimed to investigate whether there have been differences in prescription patterns of SGLT2i (using dapagliflozin as reference) in a Sanitary distric...

Introduction: The prevalence of metabolic syndrome (MetS) is increasing in patients with HIV infection on highly active antiretroviral therapy (HAART). Additionally, HCV coinfection is common among HIV patients in our area. It is widely known MetS impacts on the liver in different ways but relationship between both MetS and liver function is few studied in HIV/HVC co-infected population.Methods/design: Cross-sectional study including 35 HIV/HVC co-infect...

Introduction: The use of glucagon like peptide 1 analogues (GLP1a) for the treatment of type 2 diabetes mellitus (T2DM) is growing. After a decade-long effort to improve the pharmacokinetics of GLP1, a number of GLP1a are currently available on the market. With a view to identifying patient characteristics that could influence physicians’ prescription of different GLP1a we carried out this observational study in routine clinical practice conditions. Outcomes after add-on ...